Gene Therapy for Arthritis Using a Doxycycline-Regulated Plasmid
Author Information
Author(s): David Gould, Nasim Yousaf, Fatah Rewas, Maria Cristina Subang, Yuti Chernajovsky
Primary Institution: Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London
Hypothesis
Can gene therapy using a doxycycline-regulated plasmid encoding a TNF-alpha inhibitor effectively treat experimental arthritis?
Conclusion
The study found that the doxycycline-regulated plasmid significantly inhibited the progression of arthritis in mice.
Supporting Evidence
- Luciferase expression was regulated approximately 1,000-fold in vitro.
- Intramuscular delivery of the plasmid with electroporation was effective.
- Administration of doxycycline with the plasmid significantly reduced clinical scores in mice.
- Regulated expression of dTNFR was observed in vivo.
- Plasmid DNA was shown to persist long-term in transfected cells.
Takeaway
Scientists created a special DNA that can help treat arthritis by turning on and off a medicine when needed, and it worked well in mice.
Methodology
The study involved constructing plasmid vectors, transfecting various cell lines, and administering the plasmids to mice with collagen-induced arthritis, followed by monitoring disease progression.
Potential Biases
Potential bias in the selection of animal models and the administration of treatment.
Limitations
The study was conducted in mice, and the results may not directly translate to humans.
Participant Demographics
DBA/1 mice, aged 10 to 12 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website